Digital Health

AI-discovered drugs achieve 80-90% Phase I success rate

AI native biotech firms are significantly outperforming industry averages in identifying drug-like molecules, potentially reducing R&D costs.

Growth of 'uncontrolled experiment' in AI-driven mental health therapy

Mental health systems gain low-cost access but face new risks regarding patient surveillance and algorithmic bias in suicide prevention.

Surgical robotics dependency driven by medical training methods

Hospitals are forced to invest in expensive robots to attract physician talent rather than based on superior clinical outcomes.

AbbVie paid $100 million upfront for a trispecific T-cell binder from Zejing Biopharmaceutical, while Gilead committed $25 million to Repare Therapeutics for a BRCA-targeting inhibitor.

Innovaccer secured a statewide partnership to provide its AI platform for California’s $140 million Medi-Cal EPT Program, covering 2 million patients.

Ultragenyx initiated a cost-cutting drive after its Phase 3 brittle bone disease drug failed to meet primary endpoints, causing shares to fall 43%.

Medtronic is set to launch a more affordable surgical robot in 2026, which could disrupt Intuitive Surgical's market dominance.

Monitoring the 60-day RFI period for the FDA's VC sponsorship model to see which firms participate first.

Watch for further federal court rulings on injunctions against Trump's LGBTQ+ health mandates.